Ryaltris is the only fixed-dose combination of olopatadine hydrochloride and mometasone furoate approved by the USFDA for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older. Glenmark developed the drug, while Hikma will commercialise it in the US market.
